Prognostic Factors for Lymph Node Negative Stage I and IIA Non-small Cell Lung Cancer: Multicenter Experiences |
Ustaalioglu, Bala Basak Oven
(Department of Medical Oncology, Haydarpasa Numune Education and Research Hospital)
Unal, Olcun Umit (Eylul University Medical Faculty) Turan, Nedim (Gazi University Medical Faculty) Bilici, Ahmet (Department of Medical Oncology, Medipol University) Kaya, Serap (Kocaeli University Medical Faculty) Eren, Tulay (Ankara Numune Education and Research Hospital) Ulas, Arife (Ankara Oncology Hospital) Inal, Ali (Dicle University Medical Faculty) Berk, Veli (Erciyes University Medical Faculty) Demirci, Umut (Ataturk Education and Research Hospital) Alici, Suleyman (Department of Medical Oncology, Medical Park Hospital) Bal, Oznur (Ankara Numune Education and Research Hospital) Benekli, Mustafa (Gazi University Medical Faculty) Gumus, Mahmut (Department of Medical Oncology, Kartal Education and Research Hospital) |
1 | Ioannidis G, Georgoulias V, Souglakos J (2011). How close are we to customizing chemotherapy in early non-small cell lung cancer? Ther Adv Med Oncol, 3, 185-205. DOI ScienceOn |
2 | Kato H, Ichinose Y, Ohta M, et al (2004). Japan lung cancer research group on postsurgical adjuvant chemotherapy. a randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med, 350, 1713-21. DOI ScienceOn |
3 | Kelsey CR, Marks LB, Hollis D, et al (2009). Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer, 115, 5218-27. DOI ScienceOn |
4 | Pignon JP, Tribodet H, Scagliotti GV, et al (2008). LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol, 26, 3552-9. DOI ScienceOn |
5 | Sangha R, Price J, Butts CA (2010). Adjuvant therapy in non-small cell lung cancer: current and future directions. Oncologist, 15, 862-72. DOI ScienceOn |
6 | Strauss GM, Herndon JE 2nd, Maddaus MA, et al (2008). Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the cancer and leukemia group B, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol, 26, 5043-51. DOI ScienceOn |
7 | Suehisa H, Toyooka S (2009). Adjuvant chemotherapy for completely resected non-small-cell lung cancer. Acta Med Okayama, 63, 223-30. |
8 | Sun Z, Aubry MC, Deschamps C, et al (2006). Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg, 131, 1014-20. DOI ScienceOn |
9 | Visbal AL, Leighl NB, Feld R, et al (2005). Adjuvant chemotherapy for early-stage non-small cell lung cancer. Chest, 128, 2933-43. DOI ScienceOn |
10 | Wang WL, Shen-Tu Y, Wang ZQ (2011). Prognostic Factors for survival of stage IB upper lobe non-small cell lung cancer patients: a retrospective study in Shanghai, China. Chin J Cancer Res, 23, 265-70. DOI ScienceOn |
11 | Winget M, Fleming J, Li X, et al (2011). Uptake and tolerance of adjuvant chemotherapy in early stage NSCLC patients in Alberta, Canada. Lung Cancer, 72, 52-8. DOI ScienceOn |
12 | Zhang Z, Wang A, Zhan Z, et al (2012). T1aN0M0 and T1bN0M0 non-small cell lung cancer: a retrospective study of the prognosis. Thorac Cardiovasc Surg, [Epub ahead of print]. |
13 | Carbone DP, Felip E (2011). Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms. Clin Lung Cancer, 12, 261-71. DOI ScienceOn |
14 | Arriagada R, Dunant A, Pignon JP, et al (2010). Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol, 28, 35-42. DOI ScienceOn |
15 | Bouchard N, Laberge F, Raby B, et al (2008). Adjuvant chemotherapy in resected lung cancer: two-year experience in a university hospital. Can Respir J, 15, 270-4. DOI |
16 | Butts CA, Ding K, Seymour L, et al (2010). Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol, 28, 29-34. DOI ScienceOn |
17 | Cho S, Park TI, Lee EB, et al (2012). Poor prognostic factors in surgically resected stage I non-small cell lung cancer: histopathologic and immunohistochemical analysis. Korean J Thorac Cardiovasc Surg, 45, 101-9. DOI ScienceOn |
18 | Custodio AB, Gonzalez-Larriba JL, et al (2009). Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. J Thorac Oncol, 4, 891-910. DOI ScienceOn |
19 | Custodio AB, Garcia Saenz JA, et al (2008). Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review. Clin Transl Oncol, 10, 560-71. DOI |
20 | Edge SB, Byrd DR, Compton CC (2010). AJCC Cancer Staging Manual, Seventh Edition. New York:Springer, 1-730. |
![]() |